Inhibition of mTOR in DCs has been shown to improve their antigen presentation capabilities and enhance the activation of cytotoxic CD8 + T lymphocytes, resulting in increased antitumor activity.223,224 Therefore, mTOR inhibitors hold promise for enhancing the efficacy of tumor immunotherapy and autologous DC-based vaccination by extending the life span of DCs and improving their antigen-processing abilities. The gene discussed is MTOR; the disease is neoplasm.